Glenmark Pharmaceuticals Inc., of Paramus, N.J., presented findings from a phase IIa study of GBR 830, an investigational anti-OX40 monoclonal antibody that evaluated the safety, biological and clinical activity, and pharmacokinetics of GBR 830 in 64 patients with moderate-to-severe atopic dermatitis (AD).